PMN实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 04:00):

Stats
今日成交量	1 617.00
平均成交量	17 011.00
市值	36.49M
EPS	$0 ( 2024-04-03 )
下一个收益日期	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.800
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Warma Neil K	Buy	200 000	Option (right to buy)
2023-12-04	Sclar Jeremy M.	Buy	150 000	Series 2 Preferred Shares, no par value
2022-10-11	Sclar Jeremy M.	Buy	26 217	Warrants to Purchase Common Shares, no par value
2023-12-04	Sclar Jeremy M.	Sell	150 000	Series 1 Preferred Shares, no par value
2023-12-25	Title 19 Promis	Sell	0	Common Shares, no par value

INSIDER POWER
-43.18
Last 83 transactions
Buy: 847 135 \| Sell: 2 093 488

ProMIS Neurosciences, 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

ProMIS Neurosciences, 财务报表

Annual	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-1.070

FY	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-1.070

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-1.700

Financial Reports:

No articles found.

ProMIS Neurosciences,

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.